The Food and Drug Administration approved on Friday a new drug developed by Syndax Pharmaceuticals to treat patients with a genetically defined form of advanced leukemia.
The pill, called Revuforj, is the first medicine in a class of drugs called menin inhibitors to reach the market.
Revuforj was approved to treat adults and children with relapsed or refractory leukemias that have a genetic “rearrangement” called KMT2A. This particular genetic type of leukemia is present in approximately 10% of cases, and is difficult to treat, leading to high relapse rates and survival of less than a year.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
